Dermira Inc. (NASDAQ:DERM) CFO Andrew Guggenhime sold 4,100 shares of the firm’s stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $35.02, for a total transaction of $143,582.00. Following the transaction, the chief financial officer now owns 9,216 shares of the company’s stock, valued at approximately $322,744.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Andrew Guggenhime also recently made the following trade(s):

  • On Tuesday, October 11th, Andrew Guggenhime sold 10,900 shares of Dermira stock. The stock was sold at an average price of $34.34, for a total transaction of $374,306.00.
  • On Monday, September 19th, Andrew Guggenhime sold 15,000 shares of Dermira stock. The stock was sold at an average price of $35.01, for a total transaction of $525,150.00.
  • On Monday, September 12th, Andrew Guggenhime sold 10,000 shares of Dermira stock. The stock was sold at an average price of $32.53, for a total transaction of $325,300.00.

Dermira Inc. (NASDAQ:DERM) opened at 35.15 on Monday. The company’s market cap is $1.25 billion. Dermira Inc. has a 1-year low of $17.42 and a 1-year high of $36.34. The stock has a 50 day moving average of $33.01 and a 200-day moving average of $31.21.

Dermira (NASDAQ:DERM) last announced its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.72) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.72). On average, equities research analysts predict that Dermira Inc. will post ($3.41) earnings per share for the current year.

Insider Buying and Selling by Quarter for Dermira (NASDAQ:DERM)

A number of hedge funds and other institutional investors have recently made changes to their positions in DERM. Monashee Investment Management LLC raised its position in shares of Dermira by 385.1% in the second quarter. Monashee Investment Management LLC now owns 125,965 shares of the biopharmaceutical company’s stock worth $3,684,000 after buying an additional 100,000 shares during the period. Glenmede Trust Co. NA bought a new position in shares of Dermira during the second quarter worth approximately $170,000. Teachers Advisors Inc. raised its position in shares of Dermira by 1.9% in the first quarter. Teachers Advisors Inc. now owns 123,531 shares of the biopharmaceutical company’s stock worth $2,555,000 after buying an additional 2,278 shares during the period. AXA bought a new position in shares of Dermira during the first quarter worth approximately $1,911,000. Finally, American Century Companies Inc. bought a new position in shares of Dermira during the second quarter worth approximately $1,352,000. Institutional investors and hedge funds own 83.59% of the company’s stock.

DERM has been the subject of a number of analyst reports. Needham & Company LLC restated a “positive” rating and set a $46.00 price target on shares of Dermira in a research note on Monday, October 3rd. Leerink Swann reiterated a “buy” rating on shares of Dermira in a research note on Wednesday, October 5th. Finally, Zacks Investment Research upgraded shares of Dermira from a “sell” rating to a “hold” rating in a research note on Tuesday, August 2nd. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Dermira presently has a consensus rating of “Buy” and a consensus price target of $41.00.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.

5 Day Chart for NASDAQ:DERM

Receive News & Stock Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related stocks with our FREE daily email newsletter.